Gantenerumab does not slow clinical decline in early Alzheimer disease, research finds
by Elana GotkineThe use of gantenerumab leads to lower amyloid plaque burden at 116 weeks, but is not associated with slower clinical decline among patients with early Alzheimer disease, according to
Updated on: February 24,2024
18
Gantenerumab does not slow clinical decline in early Alzheimer disease, research finds
by Elana GotkineThe use of gantenerumab leads to lower amyloid plaque burden at 116 weeks, but is not associated with slower clinical decline among patients with early Alzheimer disease, according to
Updated on:February 24,2024
18
